Effect of liraglutide on glucagon secretion in obese type 2 diabetic patients

To investigate the effect of liraglutide on glucagon release in obese type 2 diabetes (T2DM). A multi-center, prospective, and self-comparison study was conducted in four hospitals in Qingdao. Twenty-four patients with T2DM were selected and treated with liraglutide for 12 weeks. Glucagon levels bef...

Full description

Saved in:
Bibliographic Details
Published in:Chung-hua nei kʿo tsa chih Vol. 58; no. 1; p. 33
Main Authors: Sun, X F, Wang, Y, Zhao, W J, Wang, L, Bao, D Q, Qu, G R, Yao, M X, Luan, J, Wang, Y G, Yan, S L
Format: Journal Article
Language:Chinese
Published: China 01-01-2019
Subjects:
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To investigate the effect of liraglutide on glucagon release in obese type 2 diabetes (T2DM). A multi-center, prospective, and self-comparison study was conducted in four hospitals in Qingdao. Twenty-four patients with T2DM were selected and treated with liraglutide for 12 weeks. Glucagon levels before and after treatment were detected before and 30 min, 60 min and 120 min after meals. After 12 weeks of treatment, the overall level of glucagon decreased, in which the differences in glucagon levels at 30 min [(220±79) ng/L vs. (203±77) ng/L, 0.05] and 60 min [(248±119) ng/L vs. (203±82)ng/L, 0.05] reached significance, respectively, comparing to those before treatment. The area under the curve of glucagon after treatment was significantly lower than that before treatment (438±190 vs. 389±153, 0.05). In contrast, after treatment, the overall level of C-peptide increased, especially the levels at 30 min [(1.53±1.02) nmol/L vs.(2.03±1.29) nmol/L], 60 min [(1.93±1.19) nmol/L vs. (2.48±1.75) nmol/L] and 120 min [(2
ISSN:0578-1426
DOI:10.3760/cma.j.issn.0578-1426.2019.01.006